Previous 10 | Next 10 |
Company Overview Frequency Therapeutics ( FREQ ) is a clinical-stage company targeting sensorineural hearing loss ((SNHL)). SNHL, currently, affects more than 40M people in the US and that number is expected to grow by 20% over the next decade, representing a substantial domestic market. The...
Frequency Therapeutics ( FREQ +14.1% ) announces new data from a longer-term durability study of FX-322, demonstrating that some patients with chronic sensorineural hearing loss (SNHL) had significant improvement in key measures of hearing that were sustained for up to 21 months. ...
Evidence of Durable Hearing Improvements in Follow-Up with Patients from Phase 1/2 Study; Speech Intelligibility and Audibility Sustained for Up to 21 Months After Initial Dosing Data Highlighted at the 2020 American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following ...
Frequency Therapeutics (NASDAQ: FREQ ) : Q2 GAAP EPS of -$0.19 beats by $0.03 . Revenue of $8.52M beats by $2.38M . Press Release More news on: Frequency Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Expects to Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss by Early Q4 2020; Study Readout Anticipated in Q2 2021 Recently Announced Clinical Data Show FX-322 Delivery to the Cochlea and Preliminary Evidence of a Durable Clinical Benefit; Plans New Studie...
Frequency Therapeutics (NASDAQ: FREQ ) to sell ~2.4M shares at $18/share via private placement, for gross proceeds of $42.3M. More news on: Frequency Therapeutics, Inc., Healthcare stocks news, , Read more ...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has agreed to sell 2,350,108 shares of its common st...
The following slide deck was published by Frequency Therapeutics, Inc. in conjunction with this Read more ...
Frequency Therapeutics ( FREQ ), which is a biotechnology company that focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, most recently reported its first-quarter results and provided top line data from its exploratory ...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...